




RealRate

# PHARMACEUTICAL 2012

Filana Therapeutics INC  
Rank 104 of 196



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Filana Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Filana Therapeutics INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 109% points. The greatest weakness of Filana Therapeutics INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 105% points.

The company's Economic Capital Ratio, given in the ranking table, is 248%, being 14% points above the market average of 234%.

| Input Variable                              | Value in 1000 USD |
|---------------------------------------------|-------------------|
| Assets, Current                             | 98,489            |
| Cost of Goods Sold                          | 0                 |
| Intangible Assets                           | 0                 |
| Liabilities, Current                        | 13,272            |
| Liabilities, Non-Current                    | 0                 |
| Other Assets                                | 352               |
| Other Compr. Net Income                     | 0                 |
| Other Expenses                              | 0                 |
| Other Liabilities                           | 41,298            |
| Other Net Income                            | 0                 |
| Other Revenues                              | 12,385            |
| Property and Equipment                      | 122               |
| Research and Development                    | 8,300             |
| Selling, General and Administrative Expense | 6,698             |

| Output Variable              | Value in 1000 USD |
|------------------------------|-------------------|
| Assets                       | 98,963            |
| Liabilities                  | 54,570            |
| Expenses                     | 14,998            |
| Revenues                     | 12,385            |
| Stockholders Equity          | 44,393            |
| Net Income                   | -2,613            |
| Comprehensive Net Income     | -2,613            |
| BaseVar                      | 90,458            |
| ECR before Limited Liability | 123%              |
| Economic Capital Ratio       | 248%              |